Serum testosterone levels in patients with chronic obstructive pulmonary disease

Tzu Chi Medical Journal

Volumn 18, Issue 2, 2006, Pages

  Hsu, Ai Hsi ^a   Chen, Din Yaung ^a   Lee, Jen Jyh ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Body mass index; Chronic obstructive pulmonary disease; Testosterone

Indexed keywords

ANABOLIC AGENT; TESTOSTERONE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; HUMAN; HYPOGONADISM; MALE; POPULATION DISTRIBUTION; PREVALENCE; REGRESSION ANALYSIS; STUDENT T TEST; TESTOSTERONE BLOOD LEVEL;

EID: 33745089593     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rochester DF, Braun NMT: Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1995; 132:42-47.
2. Schols AM, Mostert R, Soeters PB, Wouters EF: Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991; 46:695-699.
3. Schols AM, Slangen J, Volovics L, Wouters EF: Weight Loss Is a Reversible Factor in the Prognosis of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 1998; 157:1791-1797.
4. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF: Physiological effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152:1268-1274.
5. Ferreira IM, Verreschi IT, Nery LE, et al: The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28.
6. Creutzberg EC, Wouters EF, Mostert R, Pluymers RJ, Schols AM: A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003; 124:1733-1742.
7. Van Balkom RH, Dekhuijzen PN, van der Heijden HF, Folgering HT, Fransen JA: Effects of anabolic steroids on diaphragm impairment induced by methylprednisolone in emphysematous hamsters. Eur Respir J 1999; 13:1062-1069.
8. Van Vliet M, Spruit MA, Verleden G, et al: Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Grit Care Med 2005; 172:1105-1111.
9. Laghi F, Antonescu-Turcu A, Collins E, et al: Hypogonadism in men with chronic obstructive pulmonary disease: Prevalence and quality of life. Am J Respir Grit Care Med 2005; 171:728-733.
10. Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73:1016-1025.
11. Deslypere JP, Vermeulen A: Leydig cell function in normal men: Effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984; 59:955-962.
12. Winters SJ, Troen P: Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: Evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab 1982; 55:560-565.
13. Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bammert C, Tobin MJ: Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:598-605.
14. Ellis L, Nyborg H: Racial/ethnic variations in male testosterone levels: A probable contributor to group differences in health. Steroids 1992; 57:72-75.
15. Kamischke A, Kemper DE, Castel MA, Luthke M, et al: Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11:41-45.
16. Semple PD, Beastall GH, Watson WS, Hume R: Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci 1980; 58:105-106.
17. Semple PD, Beastall GH, Watson WS, Hume R: Hypothalamic-pituitary dysfunction in respiratory hypoxia. Thorax 1981; 36:605-609.
18. Vermeulen A, Kaufman JM: Aging of the hypothalamo-pituitary testicular axis in men. Horm Res 1995; 43:25-28.
19. Yardimci S, Atan A, Delibasi T, Sunguroglu K, Guven MC: Long-term effects of cigarette-smoke exposure on plasma testosterone, luteinizing hormone and follicle-stimulating hormone levels in male rats. Br J Urol 1997; 79:66-69.
20. Creutzberg EC, Casaburi R: Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46:76-80.
21. Casaburi R, Bhasin S, Cosentino L, et al: Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:870-878.
22. Ibanez M, Aguilar JJ, Maderal MA, et al: Sexuality in chronic respiratory failure: Coincidences and divergences between patient and primary caregiver. Respir Med 2001; 95:975-979.
23. Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R: Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004; 98:906-913.
24. Rogers RM, Donahoe M, Costantino J: Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructed pulmonary disease. A randomized control study. Am Rev Respir Dis 1992; 1511-1517.
25. Rochester DF, Braun NM: Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1995; 132:42-47.
26. Scalvini S, Volterrani M, Vitacca M, et al: Plasma hormone levels and hemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996; 51:380-386.
27. Hjalmarsen A, Aasebo U, Birkeland K, Sager G, Jorde R: Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996; 22: 37-42.
28. Brodsky IG, Balagopal P, Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469-3475.
29. Vandenbergh E, Van de Woestijne KP, Gyselen A: Weight changes in the terminal stages of chronic obstructive lung disease. Relation to respiratory function and prognosis. Am Rev Respir Dis 1967; 95: 556-566.
30. Wilson DO, Rogers RM, Wright EC, Anthonisen NR: Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent postitive-pressure Breating Trial. Am Rev Respir Dis 1989; 139: 1435-1438.
31. Bhasin S, Storer TW, Berman N, et al: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7.
32. Urban RJ, Bodenburg YH, Gilkison C, et al: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269:820-826.
33. Ferreira IM, Verreschi IT, Nery LE, et al: The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28.
34. Bernard S, Whittom F, LeBlanc P, et al: Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:896-901.
35. Donahoe M, Mancino J, Costantino J, Lebow H, Rogers RM: The effect of an aggressive nutritional support regimen on body composition in patients with severe COPD and weight loss. Am J Respir Crit Care Med 1994; 149: A313.
36. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350:482-492.
37. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724-31.
38. Morley JE, Kaiser FE, Perry HM 3rd, et al: Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46:410-413.
39. Kamischke A, Kemper DE, Castel MA, et al: Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11:41-45.
40. Gosker HR, Engelen MP, van Mameren H, et al: Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutrition 2002; 76:113-119.
41. Van Balkom RH, Dekhuijzen PN, Folgering HT, Veerkamp JH, Fransen JA, van Herwaarden CL: Effects of long term low-dose methyprednisolone on rat diaphragm function and structure. Muscle Nerve 1997; 20: 983-990.
42. Koerts-de Lang E, Schols AM, Rooyackers OE, Gayan-Ramirez G, Decramer M, Wouters EF: Different effects of corticosteroid-induced muscle wasting compared with undernutrition on rat diaphragm energy metabolism. Eur J Appl Physiol 2000; 82:493-498.
43. Lewis MI, Monn SA, Sieck GC: Effect of corticosteroids on diaphragm fatigue, SDH activity, and muscle fiber size. J Appl Physiol 1992; 72:293-301.
44. Laghi F: Low testosterone in chronic obstructive pulmonary disease. Does it really matter? Am J Respir Crit Care Med 2005; 172:1069-1070.